Blood-Based Liquid Biopsy Test by INEX INNOVATE PTE LTD Singapore

INEX INNOVATE PTE LTD from Singapore has developed a revolutionary blood-based liquid biopsy test, XENA®, for the early detection of ovarian cancer. This non-invasive method requires only a sample of whole blood collected from the arm and is expected to be launched in 2023. Compared to the current CA125 screening test, it offers greatly enhanced accuracy which reduces the need for unnecessary invasive biopsies, making it a valuable tool for informed clinical decisions.

What is a Blood-Based Liquid Biopsy Test?

A blood-based liquid biopsy test is a type of diagnostic approach used to detect and monitor diseases such as cancer. It involves taking a small sample of blood from the patient and analyzing it for biomarkers that can indicate the presence of disease. The advantage of this method over traditional biopsies is that it is non-invasive and does not require any tissue samples. Additionally, it provides more accurate results than other forms of testing.

How Does XENA® Work?

XENA® works by detecting specific biomarkers present in the patient’s blood that are associated with ovarian cancer. These biomarkers are identified through an advanced laboratory technique known as mass spectrometry. Once the biomarkers have been identified, they are analyzed to determine if there is an increased risk of developing ovarian cancer. If so, further tests may be recommended in order to confirm the diagnosis.

Benefits of XENA®

XENA® offers several advantages over traditional methods of screening for ovarian cancer. Firstly, it is a non-invasive procedure that does not require any tissue samples. Secondly, it is much more accurate than the current CA125 screening test, reducing the need for unnecessary invasive biopsies. Lastly, it allows for earlier detection of ovarian cancer, allowing for more effective treatment options.

Conclusion

The development of XENA®, a blood-based liquid biopsy test for the early detection of ovarian cancer, is a major breakthrough in medical technology. Not only is it non-invasive and highly accurate, but it also provides earlier detection of the disease, allowing for more effective treatment options. We look forward to seeing XENA® become available on the market in 2023.